Purpose Therapeutic options for patients with malignant pheochromocytoma are currently limited, and therefore new treatment approaches are being sought. Targeted radionuclide therapy provides tumor-specific systemic treatments. The β-emitting radiopharmaceutical meta- At-MABG-treated mice showed significantly lower relative tumor growth during the first 38 days than the control mice. The relative tumor volumes on day 21 were 509.2% ± 169.1% in the control mice and 9.6% ± 5.5% in the mice receiving 0.56 MBq (p < 0.01). In addition, the mice treated with 0.28, 0.56 and 1.11 MBq of 211 At-MABG showed only a temporary weight reduction, with recovery in weight by day 10. Conclusion
Introduction
Approximately 10% to 25% of patients with pheochromocytoma have systemic metastasis known as malignant pheochromocytoma [1] [2] [3] . Tumor mass effects and catecholamine induce several pathological conditions [1, 4, 5] . These are associated with mortality. Patients with malignant pheochromocytoma have limited treatment options that include chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) [6, 7] , and radionuclide therapy using β-emitting meta-131 I-iodo-benzylguanidine ( 131 I-MIBG). The effects of CVD are of limited duration [6, 8] . Of these treatments, 131 I-MIBG has been shown to prolong survival [8] .
Targeted radionuclide therapy (TRT) is a target-specific systemic therapy with a simple cytotoxic mechanism that directly targets cells such as those with DNA damage from radiation [9] . 131 I-MIBG is a false analog of norepinephrine and is therefore taken into the pheochromocytoma cell via the uptake-1 mechanism [10, 11] . 131 I-MIBG, because of the cytotoxic effects of β-radiation, can improve survival in patients with malignant pheochromocytoma [12] [13] [14] . However, even with high doses of 131 I-MIBG, survival is still limited and 131 I-MIBG is associated with radiation-induced side effects such as bone marrow suppression and lung injury [15] . Therefore, new therapeutic approaches are required to treat malignant pheochromocytoma.
A new generation of TRT involves the use of α-particles. The α-particle is exclusively cytotoxic and not affected by many of the limitations associated with conventional chemotherapy and radionuclide therapy. The α-particle has high mean energy deposition (linear energy transfer, LET) and a limited range in tissue, resulting in strong therapeutic effects with minimal side effects [16] . Theoretically, 211 At-MABG should be more effective and have fewer side effects.
The therapeutic applications of α-emitters have mainly focused on 211 At, 233 Ra, 213 Bi and 225 Ac [16, 17] . For our purposes, we required an α-emitter-labeled ligand of the norepinephrine transporter. To maintain the affinity of a benzylguanidine analog for the norepinephrine transporter, we had to use an α-emitter which has similar characteristics to 131 I. Concerning the therapeutic applications of α-emitters, 211 At is a halogen and has similar characteristics to 131 I [18] . Therefore, 211 At is suitable for labeling of a benzylguanidine analog with an α-emitter, and 211 At-MABG will have characteristics similar to those of 131 I-MIBG [19] . A previous study showed in vitro cytotoxicity in neuroblastoma cells [20] . However, to date there have been no studies looking at the therapeutic effect of 211 At-MABG in neuroblastoma and pheochromocytoma in vivo in animal models. The purpose of the present study was to investigate the therapeutic effects of 211 At-MABG in a pheochromocytoma model both in vitro and in vivo.
Materials and methods

Production of 211
At and radiosynthesis of 211 At-MABG 211 At was produced and recovered as described previously [19, 21] (Supplementary material). The emitted radioactivity of 211 At was 22.1-93.2 MBq at the end of bombardment, and the radiochemical purity of 211 At was more than 99.9% at the end of recovery. Benzylguanidine analog was labeled with 211 At according to a previously published method [19] with slight modification (see a detailed description in the Supplementary material). A high-purity germanium detector was used to measure radioactivity. Radiochemical purity of 211 At-MABG was estimated using reverse-phase radio-high-performance liquid chromatography (radio-HPLC).
Cell culture
PC12 rat pheochromocytoma cells (Japanese Collection of Research Bioresources Cell Bank, Osaka, Japan) that have high norepinephrine transporter expression [22] were cultured in RPMI-1640 (Wako Pure Chemical Industries, Osaka, Japan) containing 10% horse serum (Thermo Fisher Scientific, Waltham, MA) and 5% fetal bovine serum (Serum Source International, Charlotte, NC). The cells were cultured at 37°C in humidified air containing 5% CO 2 .
Cell survival assay At-MABG for 24 h. The cells were then washed with phosphate-buffered saline (PBS), suspended in growth medium, and seeded at 400 cells/well in a 96-well plate. After incubation for 14 days, the cells were incubated with 0.5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 4 h at 37°C. Absorbance at 590 nm was measured using a plate reader (VMax; Molecular Devices, Sunnyvale, CA). Rates of cell survival were normalized to the absorbance of control cultures treated with 0 kBq/mL.
Pheochromocytoma mouse model
The animal experimental protocol was approved by the Animal Care and Use Committees of our institutions, and all animal experiments were conducted in accordance with the institutional guidelines regarding animal care and handling. PC12 cells (3 × 10 6 ) were subcutaneously inoculated into the right hind limb of female BALB/c-nu/nu mice at 5 weeks of age (CLEA Japan, Tokyo, Japan) under isoflurane anesthesia.
Biodistribution study
PC12 tumor-bearing mice (five mice per time point) were injected with 100 kBq of 211 At-MABG in 100 μL of PBS into a tail vein. The mice were killed at 1, 3, 6, 12 and 24 h after 211 At-MABG administration. Blood, tumor, and organs of interest were dissected and weighed, and radioactivity was measured using a γ-counter (ARC-7001; Aloka, Tokyo, Japan). The radioactivity of organs and tissues except the thyroid is presented as the percentage injected radioactivity dose per gram (% ID/g), and that of the thyroid as percentage injected radioactivity dose (% ID) [23] .
Dosimetry
The mean doses per unit of injected activity (grays per megabecquerel) of α-disintegrations from 211 At absorbed by each organ and tumor were estimated according to the standard method using the Medical Internal Radiation Dose formula [24, 25] At-MABG administration. Tumor size was measured using a digital caliper, and tumor volume was calculated using the formula: tumor volume (mm 3 ) = (length × width 2 )/2. Body weight loss is considered to be one of the major radiation-related side effects of radiopharmaceuticals. Therefore, we evaluated the change in body weight of the mice as a marker of radiation-related side effects [26] .
Primary endpoint after 211
At-MABG treatment When body weight loss was more than 20% compared with that at baseline (day 0), signs of a moribund state were observed, or the tumor volume had reached more than 800 mm 3 , the mouse was killed humanely by isoflurane inhalation, and the tumor was resected for histological analysis. For Kaplan-Meier survival analysis, a tumor volume of 500 mm 3 was considered the endpoint in addition to a body weight loss of more than 20%. At-MABG were evaluated as described above.
The resected tumors were fixed in 10% neutral-buffered formalin and embedded in paraffin. The tumor sections (1 μm thick) were deparaffinized and stained with hematoxylin and eosin (H&E). Immunohistochemical staining for Ki-67 was performed using rabbit anti-Ki-67 (Abcam, Cambridge, MA) and an anti-rabbit HRP/DAB detection kit (Abcam) according to the manufacturer's instructions [27] .
To evaluate systemic toxicity of 211 At-MABG, histological changes in the bone marrow, adrenal glands, and heart of the mice were analyzed on H&E-stained sections. These organs were resected from the mice at the same time as the tumors. The organs were fixed and embedded in paraffin as described above. These sections (1 μm thick) were deparaffinized and stained with H&E. Images were obtained using a NanoZoomer S60 virtual slide scanner (Hamamatsu Photonics, Shizuoka, Japan).
Statistical analysis
Continuous measures are presented as means ± standard deviation. Data were analyzed by analysis of variance with Dunnett's multiple comparison test. The survival curves for each treatment group were compared with that for the control group using the log-rank test [28] . A p value <0.05 was considered statistically significant. Statistical calculations were carried out using GraphPad Prism and Statcel 3.
Results
Chemical and biological characterization of 211
At-MABG
The radio-HPLC analysis, cell uptake assay and inhibition assay were performed to confirm that the product was 211 At-MABG. The retention time (t R ) of the product was 19.1 min, which was close to that of nonradioactive MIBG (t R = 18.7 min); Supplementary Fig. 1 ). The radiochemical yield after HPLC purification was 61.5 ± 14.4% (decay-corrected, n = 4) and the radiochemical purity was over 99.7%. The cell uptake assay showed that the product was rapidly transported into PC12 cells that have high norepinephrine transporter expression ( Supplementary  Fig. 2a ). The inhibition assay showed that desipramine (DMI), a selective inhibitor of the norepinephrine transporter, and dl-norepinephrine significantly inhibited cell uptake of the product (p < 0.01, Supplementary Fig. 2b ), and uptake was also significantly suppressed by incubation at 4°C.
In vitro tumor cell-damaging effects of At-MABG treatment, as shown using the MTT assay (p < 0.01,vs. control; Fig. 1a) . 211 At-MABG treatment induced lactate dehydrogenase (LDH) release (a cell death marker) from PC12 cells (p < 0.01,vs. control; Supplementary Fig. 3 ).
211 At-MABG treatment dosedependently increased the proportion of cells with DNA DSB and the percentages of cells with DNA DSB treated with 2.0 and 6.0 kBq/mL 211 At-MABG were significantly higher than that in the control group (p < 0.05 for 2.0 kBq/ mL, p < 0.01 for 6.0 kBq/mL; Fig. 1b ).
In vivo study
Biodistribution and dosimetry studies At-MABG in tumors was higher than that in other organs and tissues at all time points (Table 1) .
211
At-MABG rapidly accumulated in tumors, and tumor uptake at 1 h after injection reached approximately 30% ID/g. The highest tumor uptake was reached at 3 h, and thereafter uptake decreased gradually. However, accumulation remained high at 24 h. PC12 tumors showed high absorbed doses of Table 2 ). Compared with other normal organs and tissues, the adrenal gland and heart with high norepinephrine transporter expression showed relatively high uptake ( Table 1 ). The estimated doses absorbed by the adrenal gland and heart were 5.07 and 4.08 Gy/MBq, respectively (Table 2) .
Tumor volume reduction after 211
At-MABG treatment There were no significant differences in tumor volumes at baseline (day 0) among the control group and the six 211 At-MABG treatment groups. The control group showed rapid growth of PC12 tumors (48.9 ± 7.7 mm 3 on day 0 to 591.8 ± 178.1 mm 3 on day 21, p < 0.01). The 211
At-MABG treatment groups showed significant dose-dependent reductions in tumor volume (Fig. 2a) . In mice injected with 0.28 MBq of 211 At-MABG tumor growth was suppressed until day 7 (58.2 ± 19.4 mm 3 on day 0, 59.2 ± 16.8 mm 3 on day 7, p = 0.844), but the tumors grew thereafter. In mice injected with 0.56 and 1.11 MBq of 211 At-MABG, tumor volume was rapidly reduced. Thus, we observed reductions in tumor volumes on day 1 (Fig. 2a) . The smallest tumor volumes were reached around day 21 (0.56 MBq, 48.9 ± 7.8 mm 3 on day 0 to 4.5 ± 2.3 mm 3 on day 21, p < 0.01; 1.11 MBq, 48.7 ± 8.0 mm 3 on day 0 to 1.7 ± 1.9 mm 3 on day 21, p < 0.01; Fig. 2a, b) . Therefore, in the control group tumor volume increased by 409.% ± 169.1% from day 0 to day 21, whereas tumor volumes in the mice injected with 0.56 and 1.11 MBq of 211 At-MABG decreased by 90.4 ± 5.5% and 96.7% ± 3.4% from day 0 to day 21, respectively (p < 0.01, vs. control; Fig. 2c ). In two 
Absorbed radiation dose
The estimated radiation dose absorbed by PC12 tumors was 10.21 Gy/MBq ( At-MABG was almost equivalent to that of 30 Gy of external X-ray irradiation ( Supplementary Fig. 4 ).
Weight change after 211
At-MABG treatment 211 At-MABG treatment caused a dose-dependent decrease in body weight soon after administration (Fig. 4) . On day 3 after injection, all the mice injected with 0.28 and 0. At-MABG showed a decrease in body weight of 10-20% (p ≤ 0.01), and a decrease in body weight of 20% was observed in one of the five mice 3 days after injection. However, the body weight decrease in all these mice was temporary, and in these groups body weight gradually recovered. As a result, there were no differences in body weight of the mice treated with 0.28, 0.56 and 1.11 MBq At-MABG compared with that of the control group on day 10 after injection (p = 0.154).
In contrast, all mice treated with 1.85, 3.70 and 5.55 MBq 211
At-MABG showed decreases in body weight of more than 20% on day 3 or 4 after 211 At-MABG administration, and were therefore killed humanely at that time. Their tumors were resected and used for histological analysis. Based on these Tumor sections were stained with H&E and Ki-67 as a proliferation marker. In sections of control tumors (0 MBq), the cells were arranged in a nest pattern and were surrounded by fibrovascular stroma (Fig. 5, left upper panel) . In sections of tumors from mice treated with 211 At-MABG, there were no nests of tumor cells, whereas hemorrhage and lymphocyte infiltration were observed (Fig. 5, left panels) . The hemorrhage increased in a time-dependent manner, and a small necrotic area was observed on day 3, and the area had expanded by day 7 (Fig. 5, left panels) . In Ki-67-stained sections of tumors from mice treated with 211 At-MABG, proliferating (Ki-67-positive) tumor cells tended to decrease in a timedependent manner (Fig. 5, right panels) .
Sections of tumors from mice treated with 1.85 MBq
211
At-MABG showed larger hemorrhage and necrotic areas than following treatment with 1.11 MBq At-MABG, partial replacement by fibrous tissue was also observed in addition to hemorrhage and necrosis (Fig. 6, left panels) . The area of fibrous tissue was larger following treatment with 5.55 MBq 211 At-MABG (Fig. 6 , left panels). In Ki-67-stained sections, proliferating tumor cells tended to decrease in a time-dependent manner (Fig. 6 , left panels).
Histological changes in bone marrow, adrenal gland, and heart after 211
At-MABG treatment
In sections of bone marrow from mice treated with 1.11 MBq 211 At-MABG, dilated vascular sinuses filled with erythrocytes were observed on day 1 after 211 At-MABG administration. The number of myeloid cells showed a slight decrease on day 3. However, on day 7 after administration of 1.11 MBq 211 At-MABG, the number of myeloid cells had recovered to the same level as in control mice (Fig. 7a) . In the adrenal gland and the heart from mice treated with 1.11 MBq 211 At-MABG, histological changes were not observed on days 1, 3 and 7 (Fig. 7a) .
Sections of femur from mice killed 3 or 4 days after administrations of 1.85, 3.70 and 5.55 MBq 211 At-MABG showed decreases in bone marrow cellularity and increases in density of erythrocytes within the expanded vascular sinuses in a dose-dependent manner (Fig. 7b) . In particular, administration of 5.55 MBq 211 At-MABG induced severe depletion of cells in the bone marrow, vascular dilation and hemorrhage (Fig. 7b) . Although histological changes were not observed in sections of adrenal glands from mice treated with 1. At-MABG (Fig. 7b) . Sections of heart from mice treated with 1.85, 3.70 and 5.55 MBq
211
At-MABG and mice in the control group showed no differences in morphological features (Fig. 7b ). 
Quality of 211
At-MABG
The radiochemical purity of 211 At-MABG was more than 99.7%. In addition, the selective norepinephrine transporter inhibitor DMI as well as norepinephrine inhibited cell uptake of the radiolabeled product. These results agree with those of previous studies involving neuroblastoma cells [29, 30] , and indicate that the quality of the 211 At-MABG used in this study was appropriate.
In vitro tumor cell growth suppression effects of At-MABG treatment is probably due to cell death induced by DNA DSB. This cell death mechanism, as confirmed in this study, supports the hypothesis of cell injury by α-particles and is most likely the main mechanism by which 211 At-MABG causes cell death in pheochromocytoma [16, 31] .
Therapeutic effects of 211
At-MABG in PC12 tumor-bearing mice Similar to the findings of a previous study using a neuroblastoma model [20] , biodistribution studies showed that 211 At-MABG accumulated more in the adrenal gland and heart than in other organs. Both the adrenal gland and heart have a rich sympathetic nervous system. Therefore, a norepinephrine analog may accumulate more readily in these organs [32, 33] . The current data also show very high I-MIBG is usually administered at intervals of 6 weeks to 3 months [10, 11] . The lack of repeated 211 At-MABG administrations is one of the limitations of this study; future studies should focus on the effects of repeated treatments.
Histological findings on the therapeutic effects of 211
At-MABG
The histological findings of this study confirmed the effectiveness of 211 At-MABG in reducing tumor volumes. Clinical research using 131 I-MIBG has shown that most patients achieve stable disease, and that complete remission was very rare [4, 13] . These clinical data suggest that the cytotoxic effects of the β-emitting 131 I-MIBG are limited. In contrast, in this study the PC12 tumors in mice receiving higher doses of 211 At-MABG showed necrosis and fibrosis at earlier time points than tumors in mice receiving lower doses. Although careful dose setting would be necessary, it is possible that 211 At-MABG treatment could lead to complete remission in patients with malignant pheochromocytoma. In contrast, catecholamine released from damaged pheochromocytoma cells can result in catecholamine crisis. This causes hypertension and catecholamine-induced cardiomyopathy [5, 34] . Patient management after 211 At-MABG therapy should be considered as the next step prior to clinical trials. I-MIBG therapy of 3%, a partial remission rate of 27% and a stable disease rate of 52% [13] . In this study, all five mice treated with the MTD of At-MABG, tumor volumes were reduced by 96.7% compared to the volumes at baseline. Strictly speaking, although the RECIST criteria cannot be applied to our data [36] , in mice treated with the MTD of 211 At-MABG (1.11 MBq), 40% achieved complete remission and 60% had partial remission. In terms of side effects of 131 I-MIBG, the most frequently reported side effects were hematologic toxicity with grade 3 or 4 neutropenia that occurred in up to 87% and grade 3 or 4 thrombocytopenia that occurred in up to 83% [13] . Although we did not monitor complete blood cell counts before and after 211 At-MABG administration, bone marrow histological findings revealed rapid recovery of bone marrow cellularity. Therefore, 211 At-MABG may have greater therapeutic effects with fewer side effects than 131 I-MIBG.
Safety aspects of 211
At-MABG therapy
One of the greatest limitations of current TRT is radiationrelated side effects such as bone marrow suppression. Since β-emitting radiotracers have far-reaching effects, surrounding organs are irradiated and damaged [9] . On the other hand, because of the short range of α-particles (<100 μm) radiation-induced side effects are minimized in the clinical setting [37] . In this study, we measured the body weight of the mice to monitor radiation-induced adverse effects and, based on the body weight reduction, decided that the MTD of 211 At-MABG in nude mice was 1.11 MBq. Mice receiving a dose of 211 At-MABG lower than or equal to the MTD showed temporary weight reduction after administration but then a gradual recovery in body weight. Thus, there was no significant weight reduction at 10 days after 211 At-MABG administration compared with the body weight of control mice.
Changes in bone marrow cellularity indicate systemic toxicity from exposure to chemicals or radiation. Therefore, evaluation of bone marrow is important in toxicity and safety assessments [38, 39] . We evaluated bone marrow cellularity using H&E-stained femur sections. The treatment with 211 At-MABG at the MTD (1.11 MBq) caused no marked change in bone marrow cellularity compared with the bone marrow of the control group. In contrast, treatment with 1.85, 3.70 and 5.55 MBq of 211 At-MABG induced obvious decreases in the number of nucleated cells and increases in the density of erythrocytes within the dilated vascular spaces. Sections of the adrenal gland and heart that express norepinephrine transporter were also evaluated. There were no marked histological changes in any organs treated with the MTD of 211 At-MABG, whereas some vacuolated medullary cells were detected in adrenal gland treated with 3.70 and 5.55 MBq of 211 At-MABG. These results indicate that the MTD of 211 At-MABG determined in terms of body weight should be safe based on these histological findings.
Study limitations
The protocol used in this study involved a single 211 At-MABG administration because the aim was to clarify the initial therapeutic effects and to evaluate the adverse effects. Based on the current data, we determined the therapeutic MTD of 211 At-MABG. The next step will be to conduct a repeated-treatment study in the near future. We evaluated the therapeutic and adverse effects of 
Conclusions
211
At-MABG showed a strong tumor volume-reducing effect in a pheochromocytoma mouse model without severe adverse effects such as weight reduction and reductions in the numbers of myeloid cells in the bone marrow. Therefore, 211 At-MABG might be an effective therapeutic agent for the treatment of malignant pheochromocytoma.
